The rs738409 (I148M) Variant of the PNPLA3 Gene and Type 2 Diabetes in Yakutia

ORIGINAL ARTICLE
Lubov A. Sydykova, Khariton A. Kurtanov, Natalia V. Borisova, Nadejda I. Pavlova, Konstantin M. Stepanov, Sardana V. Markova, Albert D. Makarov, Sardana N. Alekseeva, Uliana D. Antipina

 
International Journal of Biomedicine. 2018;8(3):201-205.   
DOI: 10.21103/Article8(3)_OA6
Originally published September 15, 2018  

Abstract: 

The purpose of our research was to study the association of the PNPLA3 SNP rs738409 (C>G) with type 2 diabetes (T2D) in the Yakuts. The frequency distribution of alleles and genotypes of the PNPLA3 rs738409 SNP was in accordance with HWE. There were no statistically significant differences in the distribution of alleles and genotypes of the PNPLA3 SNP rs738409 (C>G)  between T2D patients and non-T2D patients (P>0.05); the G allele and homozygous GG genotype prevailed in both groups. In T2D patients, a high frequency of the G allele (74.1%) was found, with a predominance of the GG genotype (58.5%). We also found that the mutant allele frequency is higher than in the studied populations of the world. Further studies with larger sample size are required to achieve sufficient statistical power to detect the association of the PNPLA3 SNP (rs738409 with the development of T2D in Yakut patients.

Keywords: 
type 2 diabetes, gene polymorphism • non-alcoholic fatty liver disease • Yakut population
References: 
  1. Dedov II, Shestakova MV, Vikulova OK. [Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry]. Diabetes mellitus. 2017;20(1):13-41. doi: 10.14341/DM8664. [Article in Russian].
  2. Biryukova EV, Rodionova SV. [Type 2 diabetes mellitus and non-alcoholic fatty liver disease — diseases of modern times]. Medical Almanac. 2017; (6):130-5. [Article in Russian].
  3. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). J Hepatol. 2016;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. PubMed
  4. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-5. doi: 10.1038/ng.257. PubMed
  5. Zhang L, You W, Zhang H, Peng R, Zhu Q, Yao A, et al. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol. 2015;30(5):821-9. doi: 10.1111/jgh.12889. PubMed
  6. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem. 2011;286(43):37085-93. doi: 10.1074/jbc.M111.290114. PubMed
  7. Sookoian S, Pirola CJ. PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18(42):6018–26. doi: 10.3748/wjg.v18.i42.6018. PubMed
  8. Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin M, Stahlman M, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol. 2012;57(6):1276–82. doi: 10.1016/j.jhep.2012.07.030. PubMed
  9. Mancina RM, Matikainen N, Maglio C, Soderlund S, Lundbom N, Hakkarainen A, et al. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant. J Clin Endocrinol Metab. 2015;100(5):E821–5. doi: 10.1210/jc.2014-4464. PubMed
  10. Trépo E, Romeo S, Zucman-Rossi J, Nahon P. PNPLA3 gene in liver diseases. J Hepatol. 2016;65(2):399-412. doi: 10.1016/j.jhep.2016.03.011. PubMed
  11. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51(4):1209–17. doi: 10.1002/hep.23622. PubMed
  12. Trépo E, Gustot T, Degre D, Lemmers A, Verset L, Demetter P, et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol. 2011;55(4):906–12. doi: 10.1016/j.jhep.2011.01.028. PubMed
  13. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011;53(3):791–9. doi: 10.1002/hep.24123. PubMed
  14. Muller T, Buch S, Berg T, Hampe J, Stickel F. Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol. 2011;55(3):732–733. doi: 10.1016/j.jhep.2011.01.025. PubMed
  15. Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011;54(1):60–9. doi: 10.1002/hep.24350. PubMed
  16. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155-61. doi: 10.1159/000282080. PubMed
  17. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006. doi: 10.1016/j.dld.2015.08.004. PubMed
  18. Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol. 2015;7(6):846–858. doi:  10.4254/wjh.v7.i6.846. PubMed
  19. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40 Suppl 1:S17–29. PubMed
  20. Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 2008;34(6 Pt 2):634–7. doi: 10.1016/S1262-3636(08)74597-X. PubMed
  21. Petit JM, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P, et al. Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab. 2010;95(12):E430-6. doi: 10.1210/jc.2010-0814. PubMed
  22. Cox AJ, Wing MR, Carr JJ, Hightower RC, Smith SC, Xu J, et al.  Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus. Diabetes Metab. 2011;37(5):452-5. doi: 10.1016/j.diabet.2011.05.001. PubMed
  23. Huang CF, Dai CY, Yeh ML, Huang CI, Tai CM, Hsieh MH, et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection.J Hepatol. 2015 Mar;62(3):512-8. doi: 10.1016/j.jhep.2014.10.011. PubMed
  24. Posadas-Sánchez R1, López-Uribe ÁR2, Posadas-Romero C2, Pérez-Hernández N3, Rodríguez-Pérez JM3, Ocampo-Arcos WA2, et al. Association of the I148M/PNPLA3 (rs738409) polymorphism with premature coronary artery disease, fatty liver, and insulin resistance in type 2 diabetic patients and healthy controls. The GEA study.Immunobiology. 2017 Oct;222(10):960-966. doi: 10.1016/j.imbio.2016.08.008. PubMed
  25. Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Konigsrainer I, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009;58(11):2616–2623. doi: 10.2337/db09-0279. PubMed
  26. Speliotes EK, Butler JL, Palmer CD, Voight BF; GIANT Consortium; MIGen Consortium; NASH CRN, Hirschhorn JN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology.  2010;52(3):904–12. doi: 10.1002/hep.23768. PubMed

Download Article
Received May 16, 2018.
Accepted August 7, 2018.
©2018 International Medical Research and Development Corporation.